|
Market Closed -
Nasdaq
16:00:00 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 4.660 USD | -2.10% |
|
-6.99% | +63.51% |
| 08-31 | Lifeward Names Josh Hexter as Interim CEO and Rami Aviram as CFO | MT |
| 08-10 | Oramed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 194M | - | - | - | - | - |
| 45.48B | |||||
| 43.69B | - | - | - | - | - |
| 43.09B | |||||
| 39.4B | |||||
| 31.91B |
Select your edition
All financial news and data tailored to specific country editions
